Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis.

• DOI: 10.1200/jco.2024.42.16_suppl.e14683
• Publication Date: 2024-06-04T19:46:23Z
• Authors: Ruxuan Chen; Yujie Shi; Hui Huang; Mengzhao Wang; Yan Xu
• Keywords: Pneumonitis

e14683 Background: Checkpoint inhibitor pneumonitis (CIP) is a relatively uncommon but potentially life-threatening immune-related adverse event (irAE). Lung biopsies have not been commonly performed for CIP patients. Bronchoalveolar lavage fluid (BALF) analysis useful diagnostic approach interstitial lung disease. However, BALF features were inconsistent across different studies. Methods: We retrospectively reviewed the medical records of 154 patients with pathologically confirmed malignancies and suffering from CIPs between July 2018 December 2022. Patients who had bronchoalveolar (BAL) data available enrolled in our study. Patient clinical, laboratory, radiological follow-up analyzed. In study, grade 1 or 2 defined as low-grade CIPs, 3, 4 5 high-grade CIPs. Results: The differential cell count lymphocyte subset 42 There 32 males (76.2%). mean age at diagnosis was 62.0 ± 10.4 (range: 31-78) years. median time to onset 98.5 days after start immunotherapy. Most diagnosed cancer (36 patients, 85.7%). 3 esophageal squamous cancer, patient hepatic gastric signet ring pericardial malignant mesothelioma. 18 (42.9%) 24 (57.1%) percentage 36.7 22.5%. 34 (81%) lymphocytic cellular pattern. ratio CD3 + CD4 /CD3 CD8 lymphocytes 0.5 (0.3, 1.0). less than 1.0 31 (73.8%). there no significant difference those Conclusions: lymphocytosis pattern main inflammatory profile this cohort. Targeting might be treatment option